TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38288922

Group type: EXPERIMENTAL
Intervention: Adalimumab plus methotrexate (adalimumab 40 mg subcutaneously every other week + methotrexate 15 mg weekly)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Escalated methotrexate (up to 25 mg weekly)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Adalimumab responders (those who reached MDA at 16 weeks)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Methotrexate responders (those who reached MDA at 16 weeks)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Adalimumab non-responders (those who did not reach MDA at 16 weeks)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Methotrexate non-responders (those who did not reach MDA at 16 weeks)
Number of subjects: 245
Study: 38288923

Group type: EXPERIMENTAL
Intervention: Anifrolumab 300 mg intravenously once every 4 weeks for 48 weeks
Number of subjects: 726

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 726
Study: 38288936

Group type: EXPERIMENTAL
Intervention: Anifrolumab 300 mg
Number of subjects: 726

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 726
Study: 38288937

Group type: EXPERIMENTAL
Intervention: secukinumab 300 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: secukinumab 150 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: secukinumab 150 mg no loading dose (NL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: secukinumab 150 mg NL
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 38288945

Group type: EXPERIMENTAL
Intervention: Cuffless blood pressure monitoring device (Somnotouch-NIBP)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Cuff-based blood pressure monitoring device (Spacelabs 90217A/IEM Mobil-O-graph)
Number of subjects: 166
Study: 38289301

Group type: EXPERIMENTAL
Intervention: Oscillatory PEP-therapy using Acapella DHGreen device, 10-12 hours after tracheal extubation, 3 times a day for 3 days after surgery.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no respiratory therapy).
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oscillatory PEP-therapy.
Number of subjects: 60
Study: 38289602

Group type: EXPERIMENTAL
Intervention: Mobile Critical Care Recovery Program (m-CCRP) - a 12-month nurse-led collaborative care intervention supported by an interdisciplinary team.
Number of subjects: 466

Group type: COMPARATOR
Intervention: Control group - telephone-based intervention.
Number of subjects: 466
Study: 38289603

Group type: EXPERIMENTAL
Intervention: Laparoscopic Sleeve Gastrectomy (SG)
Number of subjects: 1735

Group type: COMPARATOR
Intervention: Laparoscopic Roux-en-Y Gastric Bypass (RYGB)
Number of subjects: 1735
Study: 38289604

Group type: EXPERIMENTAL
Intervention: Advance Care Planning (ACP) intervention conducted by health care workers; 45- to 60-minute discussions, conducted remotely after March 13, 2020.
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Advance Care Planning (ACP) intervention
Number of subjects: 426

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 426
Study: 38289663

Group type: EXPERIMENTAL
Intervention: 10-week self-guided mindfulness-based stress reduction workbook program (e-book or paper option)
Number of subjects: 25

Group type: COMPARATOR
Intervention: 10-week wait (control group)
Number of subjects: 25
Study: 38289666

Group type: EXPERIMENTAL
Intervention: VR therapy (360° VR films on a head-mounted display for up to 20 minutes every 1 to 3 days)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 69
Study: 38289673

Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation Training (PMRT) with Personalized Virtual Reality (VR) exposure
Number of subjects: 72

Group type: COMPARATOR
Intervention: Progressive Muscle Relaxation Training (PMRT) with Guided Imagery (GI) exposure
Number of subjects: 72
Study: 38289823

Group type: EXPERIMENTAL
Intervention: Powered Toothbrush (PTB)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Manual Toothbrush (MTB)
Number of subjects: 328
Study: 38289907

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Omicron and Delta variants
Number of subjects: 0
Study: 38289999

Group type: EXPERIMENTAL
Intervention: Mineralocorticoid receptor antagonist
Number of subjects: 0
Study: 38290108

Group type: EXPERIMENTAL
Intervention: Venetoclax 400 mg daily after initial ramp-up until progressive disease
Number of subjects: 158
Study: 38290135

Group type: EXPERIMENTAL
Intervention: Add-on parsaclisib 10 or 20 mg, once daily for 8 weeks, then once weekly thereafter (daily-to-weekly dosing)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Add-on parsaclisib 5 or 20 mg, once daily for 8 weeks, then 5 mg once daily thereafter (all-daily dosing)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Add-on parsaclisib (daily-to-weekly dosing)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Add-on parsaclisib (all-daily dosing)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Add-on parsaclisib
Number of subjects: 74
Study: 38290574

Group type: EXPERIMENTAL
Intervention: Individualized nutritional support
Number of subjects: 2028

Group type: COMPARATOR
Intervention: Usual care nutrition
Number of subjects: 2028

Group type: EXPERIMENTAL
Intervention: Adapted NRS
Number of subjects: 2028

Group type: EXPERIMENTAL
Intervention: Original NRS and MNA
Number of subjects: 2028

Group type: EXPERIMENTAL
Intervention: Adapted MNA
Number of subjects: 2028
Study: 38290699

Group type: EXPERIMENTAL
Intervention: Cinnamon (4 g/d)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 38290741

Group type: EXPERIMENTAL
Intervention: Cold application (cold gel packs applied 12 times for 15 min at 2-h intervals)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (patients receiving amiodarone treatment without cold application)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Cold application
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 79
Study: 38290758

Group type: EXPERIMENTAL
Intervention: AI-assisted colonoscopy (AI-C)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Conventional colonoscopy (CC)
Number of subjects: 240
Study: 38290769

Group type: EXPERIMENTAL
Intervention: Oligo-fractionated irradiation (22.5 Gy/5 fractions/5 days) followed by nivolumab every 2 weeks
Number of subjects: 20
Study: 38290996

Group type: EXPERIMENTAL
Intervention: Interdisciplinary periodontal-orthodontic treatment (mucogingival surgery using subepithelial connective tissue graft followed by orthodontic treatment)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Mucogingival surgery alone (control group)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Interdisciplinary periodontal-orthodontic treatment
Number of subjects: 36
Study: 38291017

Group type: EXPERIMENTAL
Intervention: Neuroendoscopic hematoma evacuation surgery
Number of subjects: 560

Group type: COMPARATOR
Intervention: Standard conservative treatment
Number of subjects: 560
Study: 38291174

Group type: EXPERIMENTAL
Intervention: Epidural analgesia with programmed intermittent bolus plus patient-controlled epidural analgesia regimen
Number of subjects: 30
Study: 38291214

Group type: EXPERIMENTAL
Intervention: Positive social support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Detrimental interactions
Number of subjects: 0
Study: 38291279

Group type: EXPERIMENTAL
Intervention: Bamlanivimab (BAM) 175 mg + Etesevimab (ETE) 350 mg
Number of subjects: 927

Group type: EXPERIMENTAL
Intervention: Bamlanivimab (BAM) 700 mg + Etesevimab (ETE) 1400 mg
Number of subjects: 927

Group type: EXPERIMENTAL
Intervention: Bamlanivimab (BAM) 2800 mg + Etesevimab (ETE) 2800 mg
Number of subjects: 927

Group type: EXPERIMENTAL
Intervention: Bamlanivimab (BAM) 700 mg alone
Number of subjects: 927

Group type: EXPERIMENTAL
Intervention: Bamlanivimab (BAM) 350 mg + Etesevimab (ETE) 700 mg
Number of subjects: 927

Group type: EXPERIMENTAL
Intervention: Bamlanivimab (BAM) 700 mg + Sotrovimab 500 mg
Number of subjects: 927

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 927
Study: 38291280

Group type: EXPERIMENTAL
Intervention: Kukoamine B mesylate (KB) at doses of 0.005 mg/kg, 0.02 mg/kg, 0.04 mg/kg, 0.08 mg/kg, 0.12 mg/kg, 0.24 mg/kg, 0.48 mg/kg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 38291301

Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Vegan diet
Number of subjects: 20
Study: 38291369

Group type: EXPERIMENTAL
Intervention: Woebot for Mood & Anxiety (W-MA-02)
Number of subjects: 256
Study: 38291372

Group type: EXPERIMENTAL
Intervention: Tovorafenib, administered once weekly at 420 mg/m2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current standard of care (SoC) chemotherapy
Number of subjects: 0
Study: 38291408

Group type: EXPERIMENTAL
Intervention: Autonomous motivation
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Controlled motivation
Number of subjects: 58
Study: 38291650

Group type: EXPERIMENTAL
Intervention: Noninvasive ocular surface workup using Oculus Keratograph (K5 M)
Number of subjects: 120
Study: 38291865

Group type: EXPERIMENTAL
Intervention: Lenvatinib (12 mg for bodyweight ≥60 kg, 8 mg for bodyweight <60 kg) orally once daily, sintilimab (200 mg) intravenously once every 3 weeks, and on demand TACE
Number of subjects: 30
Study: 38291897

Group type: EXPERIMENTAL
Intervention: 0.6 million IU cholecalciferol oral
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 38291916

Group type: EXPERIMENTAL
Intervention: Favorite music
Number of subjects: 0

Group type: COMPARATOR
Intervention: White noise
Number of subjects: 0
Study: 38292039

Group type: EXPERIMENTAL
Intervention: M-M-RVaxPro
Number of subjects: 6540

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6540
Study: 38292041

Group type: EXPERIMENTAL
Intervention: Gradient Boosting Classifier (GBC) model
Number of subjects: 689
Study: 38292042

Group type: EXPERIMENTAL
Intervention: Pegzilarginase
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 38292279

Group type: EXPERIMENTAL
Intervention: Protocolized sedation and analgesia
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (without protocol)
Number of subjects: 69
Study: 38292350

Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: remdesivir
Number of subjects: 165

Group type: COMPARATOR
Intervention: standard of care
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: TFPI
Number of subjects: 165
Study: 38292386

Group type: EXPERIMENTAL
Intervention: Lifestyle Hub intervention group (LH)
Number of subjects: 106

Group type: COMPARATOR
Intervention: WL group (control)
Number of subjects: 106
Study: 38292889

Group type: EXPERIMENTAL
Intervention: Electric marking pen (Comfort Marker 2.0, CM)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Lancets
Number of subjects: 92
Study: 38293149

Group type: EXPERIMENTAL
Intervention: Small-quantity lipid-based nutrient supplements (SQ-LNS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mother-infant fucosyltransferase status and infant gut microbiome
Number of subjects: 0
Study: 38293200

Group type: EXPERIMENTAL
Intervention: Pulsed low-dose-rate radiation (PLDR) combined with chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional chemoradiation
Number of subjects: 0
Study: 38293643

Group type: EXPERIMENTAL
Intervention: Diaphragmatic ultrasound assessment within the first 24 hours of admission
Number of subjects: 68
Study: 38293926

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD), N=556
Number of subjects: 1116

Group type: COMPARATOR
Intervention: Usual care, N=550
Number of subjects: 1116
Study: 38293957

Group type: EXPERIMENTAL
Intervention: ABBV-599 (upadacitinib 15 mg plus elsubrutinib 60 mg)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: upadacitinib 15 mg
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: elsubrutinib 60 mg
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: elsubrutinib 20 mg
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: elsubrutinib 5 mg
Number of subjects: 242

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study: 38294008

Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m2)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 38294016

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (50 Allergan units) in 1 mL of saline
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline injection (1 mL)
Number of subjects: 60
Study: 38294032

Group type: EXPERIMENTAL
Intervention: Supported self-management group (n=40)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care group (n=20)
Number of subjects: 60
Study: 38294084

Group type: EXPERIMENTAL
Intervention: PLX-PAD
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: PLX-PAD (subpopulation with HbA1c < 6.5%)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo (subpopulation with HbA1c < 6.5%)
Number of subjects: 213
Study: 38294091

Group type: EXPERIMENTAL
Intervention: LY3509754 (10-2000 mg single ascending dose or 100-1000 mg multiple ascending dose for 14 days)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 38294158

Group type: EXPERIMENTAL
Intervention: Tenapanor (50 mg twice a day)
Number of subjects: 1372

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1372

Group type: EXPERIMENTAL
Intervention: Weekly CSBM status
Number of subjects: 1372
Study: 38294498

Group type: EXPERIMENTAL
Intervention: LAAO
Number of subjects: 638
Study: 38294575

Group type: EXPERIMENTAL
Intervention: Experimental or standard-of-care Enzyme Replacement Therapy (ERT)
Number of subjects: 123
Study: 38294813

Group type: EXPERIMENTAL
Intervention: Sudarshan Kriya Yoga (SKY)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Stress Management Education (SME)
Number of subjects: 129
Study: 38294848

Group type: EXPERIMENTAL
Intervention: Chance2Act intervention
Number of subjects: 124

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 124
Study: 38294865

Group type: EXPERIMENTAL
Intervention: Telemedicine plus standard care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 0
Study: 38294866

Group type: EXPERIMENTAL
Intervention: Web-based Building Resilience At Work (BRAW) program
Number of subjects: 33
Study: 38294895

Group type: EXPERIMENTAL
Intervention: CUSA Clarity Ultrasonic Surgical Aspirator System
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38294975

Group type: EXPERIMENTAL
Intervention: NTLA-2002 25 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: NTLA-2002 50 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: NTLA-2002 75 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: NTLA-2002 (all doses)
Number of subjects: 10
Study: 38294972

Group type: EXPERIMENTAL
Intervention: Butantan-DV
Number of subjects: 16235

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16235
Study: 38294974

Group type: EXPERIMENTAL
Intervention: NALL for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: NALL vs Placebo
Number of subjects: 60

Group type: COMPARATOR
Intervention: NALL and Placebo
Number of subjects: 60
Study: 38294973

Group type: EXPERIMENTAL
Intervention: 0.7% iodine povacrylex in 74% isopropyl alcohol (iodine group)
Number of subjects: 8485

Group type: COMPARATOR
Intervention: 2% chlorhexidine gluconate in 70% isopropyl alcohol (chlorhexidine group)
Number of subjects: 8485

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 8485
Study: 38295049

Group type: EXPERIMENTAL
Intervention: Camera Heart Rate Variability (CHRV) app for resonance frequency breathing training.
Number of subjects: 60
Study: 38295131

Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 57

Group type: COMPARATOR
Intervention: Palpation
Number of subjects: 57
Study: 38295144

Group type: EXPERIMENTAL
Intervention: Paclitaxel and Carboplatin with Low-intensity Pulsed Ultrasound and Microbubbles (LIPU/MB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paclitaxel (monotherapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carboplatin (monotherapy)
Number of subjects: 0
Study: 38295280

Group type: EXPERIMENTAL
Intervention: Cooccurring favorable-risk mutations (NPM1, CEBPA, t(8;21), or inv(16))
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Cooccurring poor-risk mutations (WT1, UBTF, or NUP98::NSD1)
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Intermediate risk (lacking either favorable-risk or poor-risk mutations)
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Intensified therapy (consolidation transplant in remission)
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Intensified therapy including sorafenib for ITDpos/NUP98::NSD1
Number of subjects: 464
Study: 38295317

Group type: EXPERIMENTAL
Intervention: Chemotherapy + Bevacizumab (CT + B)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Chemotherapy only (CT)
Number of subjects: 239
Study: 38295339

Group type: EXPERIMENTAL
Intervention: DaxibotulinumtoxinA 125U
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: DaxibotulinumtoxinA 250U
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study: 38295507

Group type: EXPERIMENTAL
Intervention: Cottonseed oil (CSO)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Olive oil (OO)
Number of subjects: 42
Study: 38295773

Group type: EXPERIMENTAL
Intervention: Education at the community and individual level; Intensive health wellness coaching
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel stroke biomarkers
Number of subjects: 0
Study: 38295948

Group type: EXPERIMENTAL
Intervention: T-piece
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Pressure-support ventilation (PSV)
Number of subjects: 25
Study: 38295949

Group type: EXPERIMENTAL
Intervention: High PEEP
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low PEEP
Number of subjects: 16
Study: 38295954

Group type: EXPERIMENTAL
Intervention: Ficonalkib (SY-3505) at 800 mg QD in phase 1
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Ficonalkib (SY-3505) at 600 mg QD in phase 2
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Ficonalkib (SY-3505) at 600 mg QD in phase 1/2
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Ficonalkib (SY-3505)
Number of subjects: 127
Study: 38295968

Group type: EXPERIMENTAL
Intervention: Annovera (segesterone acetate and ethinyl estradiol ring)
Number of subjects: 2064
Study: 38296197

Group type: COMPARATOR
Intervention: Dermatoscopy alone
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: Adjunctive Reflectance Confocal Microscopy (RCM)
Number of subjects: 1005
Study: 38296249

Group type: EXPERIMENTAL
Intervention: Shorter implants (6 mm)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard-length implants (11-15 mm) with sinus grafting
Number of subjects: 101
Study: 38296269

Group type: EXPERIMENTAL
Intervention: Low-field MRI (<0.5T)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Conventional neuroimaging
Number of subjects: 300
Study: 38296273

Group type: EXPERIMENTAL
Intervention: Polyphenol supplementation (one time per day for 8 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Clinician-prescribed treatment without polyphenols
Number of subjects: 60
Study: 38296274

Group type: EXPERIMENTAL
Intervention: CB-PTSD and CB-PTSS prevalence
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Impact of CB-PTSD and CB-PTSS
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Role of childbirth experience
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Social and economic determinants
Number of subjects: 300
Study: 38296279

Group type: EXPERIMENTAL
Intervention: Focal ultra-hypofractionated salvage RT with 34 Gy in five fractions every other day and 6 months of androgen deprivation therapy
Number of subjects: 36
Study: 38296283

Group type: EXPERIMENTAL
Intervention: ePROM-based systematic symptom monitoring and management intervention (completed once a month for 6 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study: 38296290

Group type: EXPERIMENTAL
Intervention: Oral ferrous fumarate
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Oral ferric maltol
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intravenous iron
Number of subjects: 90
Study: 38296293

Group type: EXPERIMENTAL
Intervention: Clemastine fumarate 4 mg two times a day for 6 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Clemastine fumarate
Number of subjects: 80
Study: 38296300

Group type: EXPERIMENTAL
Intervention: Couple-based motivational interviewing (MI-only arm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Couple-based motivational interviewing with mobile breathalysers (MI-plus arm)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced usual care (control arm)
Number of subjects: 0
Study: 38296309

Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham transplantation
Number of subjects: 31
Study: 38296588

Group type: EXPERIMENTAL
Intervention: Intravenous rhPro-UK (35 mg)
Number of subjects: 1446

Group type: COMPARATOR
Intervention: Standard medical treatment
Number of subjects: 1446
Study: 38296589

Group type: EXPERIMENTAL
Intervention: Head dOwn-Position (HDP) -20° Trendelenburg plus standard medical care
Number of subjects: 600

Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 600
Study: 38296630

Group type: EXPERIMENTAL
Intervention: Acetazolamide (375 mg/day)
Number of subjects: 521

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 521
Study: 38296802

Group type: EXPERIMENTAL
Intervention: Bimekizumab
Number of subjects: 1252
Study: 38296849

Group type: EXPERIMENTAL
Intervention: Low-dose CT pulmonary angiogram (CTPA) protocol
Number of subjects: 113
Study: 38296965

Group type: EXPERIMENTAL
Intervention: Usual care plus DMF
Number of subjects: 713

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 713
Study: 38297196

Group type: EXPERIMENTAL
Intervention: Simulation training in difficult airway management according to DAS guidelines
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Simulation training
Number of subjects: 24